← Back to Search

Individualized Cancer Therapy for Aggressive Cancers (MCW I-PREDICT Trial)

Phase 1 & 2
Recruiting
Led By Razelle Kurzrock, MD
Research Sponsored by Medical College of Wisconsin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 months
Awards & highlights

MCW I-PREDICT Trial Summary

This trial tests a new approach to individualize cancer treatments based on molecular changes in a patient's cancer. It could lead to better outcomes for patients.

Who is the study for?
Adults with aggressive solid tumors, including rare cancers or those without beneficial standard therapies. Eligible participants must have measurable disease, adequate organ function, and not be pregnant or breastfeeding. They should agree to use contraception and have no severe medical conditions that could interfere with the study.Check my eligibility
What is being tested?
The trial is testing personalized cancer treatments based on molecular profiling of individual tumors against standard care agents. It's a non-randomized study aiming to see if matching therapy to specific molecular changes in different cancers can improve outcomes.See study design
What are the potential side effects?
Potential side effects depend on the targeted agent used but may include typical reactions like fatigue, nausea, allergic responses to medication components, liver function changes, blood count variations and increased risk of infections due to immune system impact.

MCW I-PREDICT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Matched treatment
Secondary outcome measures
Actionable alterations
MTB recommended treatment

MCW I-PREDICT Trial Design

6Treatment groups
Experimental Treatment
Group I: Group 3: Targeted agentExperimental Treatment1 Intervention
Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
Group II: Group 3: Standard of care agentExperimental Treatment1 Intervention
Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 3 will comprise subjects with metastatic or unresectable disease who have received at least one prior systemic therapy, whether matched or unmatched.
Group III: Group 2: Targeted agentExperimental Treatment1 Intervention
Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
Group IV: Group 2: Standard of care agentExperimental Treatment1 Intervention
Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 2 will comprise treatment naïve subjects with metastatic disease.
Group V: Group 1: Targeted agentExperimental Treatment1 Intervention
Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
Group VI: Group 1: Standard of care agentExperimental Treatment1 Intervention
Subjects will be grouped into one of three study groups (Groups 1, 2, or 3) based on their disease status and history of prior cancer therapy. Group 1 subjects will comprise treatment naïve subjects with localized disease and (i) are eligible for neoadjuvant treatment, (ii) have unresectable disease, or (iii) are medically unfit for surgical resection.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Targeted agent
2013
N/A
~200

Find a Location

Who is running the clinical trial?

Medical College of WisconsinLead Sponsor
610 Previous Clinical Trials
1,162,313 Total Patients Enrolled
Razelle Kurzrock, MDPrincipal InvestigatorMedical College of Wisconsin
9 Previous Clinical Trials
110,290 Total Patients Enrolled
Ben George, MDPrincipal InvestigatorMedical College of Wisconsin
2 Previous Clinical Trials
30 Total Patients Enrolled

Media Library

Standard of care agent Clinical Trial Eligibility Overview. Trial Name: NCT05674825 — Phase 1 & 2
Cancer Research Study Groups: Group 3: Standard of care agent, Group 1: Targeted agent, Group 1: Standard of care agent, Group 2: Targeted agent, Group 2: Standard of care agent, Group 3: Targeted agent
Cancer Clinical Trial 2023: Standard of care agent Highlights & Side Effects. Trial Name: NCT05674825 — Phase 1 & 2
Standard of care agent 2023 Treatment Timeline for Medical Study. Trial Name: NCT05674825 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still availabilities to participate in this experiment?

"Per the clinicaltrials.gov data, there is no longer active recruitment for this particular trial which was first posted January 1st 2023 and last updated on December 23rd 2022. Nevertheless, 2734 other studies are currently seeking participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses
Ben George 2022. "Investigation of Profile-related Evidence Determining Individualized Cancer Therapy for Patients With Aggressive Malignancies and Poor Prognoses". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05674825.
~267 spots leftby Jun 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top